Clinical Trials

30 results for Kidney/Renal Cancer


Star-tor - Registry For The Evaluation Of The Safety, Tolerability And Efficacy Of Temsirolimus (Torisel®), Sunitinib (Sutent®), And Axitnib (Inlyta®) For The Treatment Of Subjects With Advanced Renal Cell Carcinoma (Mrcc), Mantle Cell Lymphoma (Mcl), And

  • Condition: Carcinoma, Renal Cell, Advanced, Lymphoma, Mantle-Cell, Gastrointestinal Stroma Tumors
  • Intervention: Drug: Temsirolimus, Drug: Temsirolimus, Drug: Sunitinib, Drug: Sunitinib, Drug: Axitinib
  • Study ID: NCT00700258
View Trial

Concurrent Chemoradiation With or Without DC-CIK Immunotherapy in Treating Locally Advanced Esophageal Cancer

  • Condition: Esophageal Carcinoma
  • Intervention: Other: concurrent chemoradiotherapy plus DC-CIK immunotherapy, Other: Concurrent chemoradiation only
  • Study ID: NCT01691625
View Trial

An Open-label, Phase II, Registry Study of Lutetium-177 [DOTA0, Tyr3] Octreotate (Lu-DOTA-TATE) Treatment in Subjects With Somatostatin Receptor Positive Tumours

  • Condition: Carcinoma, Neuroendocrine
  • Intervention: Other: Lu-DOTA-TATE radiopharmaceutical
  • Study ID: NCT01876771
View Trial

Predictors of Response to Neoadjuvant Docetaxel-Carboplatin Chemotherapy for Patients With Stage II and III Triple Negative Breast Cancer

  • Condition: Breast Cancer, Breast Cancer Stage II-III
  • Intervention: Drug: Docetaxel- Carboplatin
  • Study ID: NCT01560663
View Trial

A Randomized Phase II Study to Evaluate the Efficacy and Safety of Chemotherapy (CT) vs Androgen Deprivation Therapy (ADT) in Patients With Recurrent and/or Metastatic, Androgen Receptor (AR) Expressing, Salivary Gland Cancer (SGCs)

  • Condition: Salivary Gland Cancer
  • Intervention: Drug: bicalutamide + triptorelin, Drug: Cisplatin + Doxorubicin, Drug: Carboplatin + Paclitaxel
  • Study ID: NCT01969578
View Trial

Phase Ib Trial Of Pembrolizumab And Nintedanib

  • Condition: Patients With Any Advanced Solid Tumors.
  • Intervention: Drug: Nintedanib, Drug: Pembrolizumab
  • Study ID: NCT02856425
View Trial

A National, Prospective, Non-Interventional Study (NIS) of Nivolumab (BMS-936558) in Patients With Advanced Renal Cell Carcinoma After Prior Therapy

  • Condition: Renal Cell Carcinoma
  • Intervention: Other: Non Interventional
  • Study ID: NCT02940639
View Trial

Phase I/II Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell Carcinoma (CASA)

  • Condition: Renal Cell Carcinoma
  • Intervention: Drug: Sunitinib, Drug: Bevacizumab
  • Study ID: NCT02919371
View Trial

A First-in-Human, Open-label, Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancers

  • Condition: Neoplasms
  • Intervention: Drug: JNJ-63723283
  • Study ID: NCT02908906
View Trial

A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

  • Condition: Urothelial Carcinoma, Renal Cell Carcinoma
  • Intervention: Drug: cabozantinib, Drug: atezolizumab, Drug: cabozantinib
  • Study ID: NCT03170960
View Trial

A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (BMS-936558, Anti-PD-1 Monoclonal Antibody) in Advanced Malignant Tumors

  • Condition: Advanced Cancer
  • Intervention: Drug: BMS-986205, Drug: Nivolumab
  • Study ID: NCT02658890
View Trial

A Phase 2 Open-Label Study of Nivolumab Combined With Cabozantinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma (CA209-9KU)

  • Condition: Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma
  • Intervention: Drug: cabozantinib, Drug: nivolumab
  • Study ID: NCT03635892
View Trial

Prospective Non-interventional Study of Cabozantinib in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment

  • Condition: Advanced or Metastatic Renal Cell Carcinoma
  • Study ID: NCT03647878
View Trial

A Phase 2 Trial of PT2977 in Combination With Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

  • Condition: RCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer, Renal Cancer, Renal Cell Carcinoma, Renal Cell Cancer Metastatic, Renal Cell Carcinoma Recurrent, Renal Cell Cancer, Recurrent, Kidney
  • Intervention: Drug: PT2977 in combination with cabozantinib tablets
  • Study ID: NCT03634540
View Trial

Preventive Effects of Low-dose Aspirin as Adjuvant Therapy After Radical Nephrectomy on Disease Recurrence/Metastasis and Survival in Patients With Locally Advanced Renal Cell Carcinoma: an Observational Prospective Cohort Study

  • Condition: Aspirin as Adjuvant Therapy in Patients With Surgically Treated High Risk Renal Cell Carcinoma
  • Intervention: Drug: Low dose of aspirin
  • Study ID: NCT03734614
View Trial

A Study of Anti-PD-1( Pembrolizumab) Combinations of D-CIK (Cytokine-induced Killer Cells Are Stimulated Using Mature Dendritic Cells) Immunotherapy and Axitinib in Advanced Ranal Carcinoma

  • Condition: Renal Cancer Metastatic
  • Intervention: Biological: Combinations treatment
  • Study ID: NCT03736330
View Trial

BIOREN (Predictive BIOmarkers in Metastatic RENal Cancer) - A Translational Study on Immunotherapy for Metastatic Renal Cancer

  • Condition: Renal Cancer Metastatic
  • Intervention: Biological: Immunological and tumour characterization
  • Study ID: NCT03628859
View Trial

Molecular Analysis for Therapy Choice (MATCH)

  • Condition: Advanced Malignant Neoplasm, Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Plasma Cell Myeloma, Refractory Malignant Neoplasm, Refractory Plasma Cell Myeloma
  • Intervention: Drug: Afatinib, Drug: Akt inhibitor AZD5363, Drug: Binimetinib, Drug: Crizotinib, Other: Cytology Specimen Collection Procedure, Drug: Dabrafenib, Drug: Dasatinib, Drug: Defactinib, Drug: FGFR Inhibitor AZD4547, Other: Laboratory Biomarker Analysis, Biological: Nivolumab, Drug: Osimertinib, Drug: Palbociclib, Biological: Pertuzumab, Drug: PI3K-beta Inhibitor GSK2636771, Drug: Sapanisertib, Drug: Sunitinib Malate, Drug: Taselisib, Drug: Trametinib, Biological: Trastuzumab Emtansine, Drug: Trk Inhibitor LOXO-101, Drug: Vismodegib, Drug: WEE1 Inhibitor AZD1775
  • Study ID: NCT02465060
View Trial

FASTERCC: Folic Acid Supplement Versus Placebo for Treating Mucositis Adverse Events in Metastatic Renal Cell Carcinoma Patients Receiving Targeted Therapy. A Randomized, Double-blind Trial From the Danish Renal Cancer Group (DARENCA Study-4)

  • Condition: Mucositis
  • Intervention: Drug: Folic Acid, Drug: Placebo Oral Tablet
  • Study ID: NCT03581773
View Trial

A Phase III Study Testing the Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic Renal Cell Carcinoma Treated With Sunitinib

  • Condition: Renal Cell Carcinoma, Metastatic, Renal Cell Cancer, Recurrent
  • Intervention: Behavioral: Concomitant coaching
  • Study ID: NCT03013946
View Trial

A Phase 2 Study of Neoadjuvant Cabozantinib in Patients With Locally Advanced Non-Metastatic Clear Cell Renal Cell Carcinoma

  • Condition: Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8
  • Intervention: Drug: Cabozantinib
  • Study ID: NCT04022343
View Trial

Talazoparib and Avelumab in Genomically Defined Metastatic Renal Cell Carcinoma

  • Condition: Metastatic Renal Cell Carcinoma, Advanced Retinal Disease Carcinoma
  • Intervention: Drug: Talazoparib, Drug: Avelumab
  • Study ID: NCT04068831
View Trial

Cabozantinib in Adult Patients With Advanced Renal Cell Carcinoma Following Prior Systemic Check Point Inhibition Therapy: a Retrospective, Non-interventional Study

  • Condition: Advanced Renal Cell Carcinoma (All Subtypes), Metastatic Renal Cell Carcinoma (All Subtypes)
  • Intervention: Other: Documentation
  • Study ID: NCT04147143
View Trial

Phase II Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma. HCRN: GU16-260

  • Condition: Advanced Renal Cell Carcinoma
  • Intervention: Drug: Nivolumab 240 mg, Drug: Ipilimumab 1mg/kg, Drug: Nivolumab 3mg/kg, Drug: Nivolumab 360mg
  • Study ID: NCT03117309
View Trial

Cytoreductive Stereotactic Hypofractionated Radiotherapy With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer

  • Condition: Metastatic Renal Cell Carcinoma
  • Intervention: Drug: Ipilimumab/ Nivolumab, Radiation: SBRT + Ipilimumab/Nivolumab
  • Study ID: NCT04090710
View Trial

REPLICA: Real Patient Life Treatment With Cabozantinib in Patients With Advanced or Metastatic RCC: A Descriptive and Prospective Non-Interventional Study

  • Condition: Advanced or Metastatic Renal Cell Carcinoma
  • Study ID: NCT04106349
View Trial

A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Advanced Renal Cell Carcinoma With Bone Metastasis (RadiCal)

  • Condition: Advanced Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Collecting Duct Carcinoma, Kidney Medullary Carcinoma, Metastatic Malignant Neoplasm in the Bone, Papillary Renal Cell Carcinoma, Stage IV Renal Cell
  • Intervention: Drug: Cabozantinib, Drug: Cabozantinib S-malate, Other: Quality-of-Life Assessment, Other: Questionnaire Administration, Radiation: Radium Ra 223 Dichloride
  • Study ID: NCT04071223
View Trial

A Phase 2, Single-arm Open-label Study of Combination Nivolumab and Ipilimumab Retreatment in Advanced Renal Cell Carcinoma Patients Progressing on Nivolumab Maintenance Therapy After Nivolumab and Ipilimumab Induction

  • Condition: Renal Cell Carcinoma
  • Intervention: Biological: Nivolumab, Biological: Ipilimumab
  • Study ID: NCT04088500
View Trial

Non - Interventional, Retrospective Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint Inhibitors

  • Condition: Locally Advanced or Metastatic Renal Cell Carcinoma
  • Intervention: Drug: Cabozantinib monotherapy, Drug: All authorized TKI monotherapies in advanced RCC: sunitinib (Sutent), Pazopanib (Votrient), Axitinib (Inlyta); Lenvatinib (Lenvima) in combination with everolimus (Afinitor), sorafenib (Nexavar)
  • Study ID: NCT04353765
View Trial

A Phase 1/1b Study of Sitravatinib in Combination With Nivolumab and Ipilimumab in Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies

  • Condition: Clear-Cell Renal Cell Carcinoma
  • Study ID: NCT04518046
View Trial